Global Alzheimer’s Platform Foundation Applauds Labcorp’s Expansion of Alzheimer’s Blood Tests

Washington D.C., Mar. 20, 2024- Labcorp announced its launch of new blood tests to detect the brain protein called tau. This announcement comes on the heels of the published results of the Bio-Hermes-001 study  which reveals a strong correlation between p-tau 217 with the presence of amyloid plaques in the brain, a diagnostic hallmark of Alzheimer’s disease. 

John Dwyer, President of the Global Alzheimer’s Platform Foundation is encouraged by this announcement:

“Today, we are encouraged by Labcorp’s launch of a p-tau 217 Alzheimer’s blood test, as there is a pressing need to diagnose Alzheimer’s disease more quickly and efficiently. As we demonstrated in the published results from GAP’s Bio-Hermes study, the p-tau 217 blood marker test represents a promising pathway for providing critical information to physicians and patients about the underlying pathology that may be affecting a patient’s cognition. We applaud Labcorp for accelerating the introduction of new Alzheimer’s tests as we are convinced there will be a surge of patients asking their doctors if new disease-modifying Alsheimer’s therapies are right for them. Blood markers like p-tau 217 are solutions that can make this process faster and more reliable than ever before.”

To top